Damora Therapeutics, Inc.
DMRA
Positions held
Your positionsDMRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Damora Therapeutics operates in the biotechnology sector, which is known for its potential high returns due to innovation and unmet medical needs.
- The company's market cap is approximately $1.21 billion, indicating a significant valuation in the biotech space.
- Despite recent losses, Damora has a strong buy recommendation, suggesting investor confidence in its future potential.
- The company has reported zero revenue for multiple quarters, indicating challenges in generating income.
- In 2026-Q2, Damora reported a net income loss of -31.174 million, continuing a trend of negative earnings.
- The stock has a strong sell signal with a score of -24.00, reflecting bearish market sentiment and technical indicators.
Fundamentals
| Market cap | $1.27B | Enterprise value | $858.76M | Trailing P/E | — | Forward P/E | -9.46 |
| PEG | — | Price / book | 3.29 | Beta | 1.44 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -99.7% | ROA | -21.6% | Debt / equity | — |
| Current ratio | 19.73 | Free cash flow | -$15.98M | Analyst recommendation | strong_buy | Mean target | $46.89 |
| 52w high | $38.33 | 52w low | $4.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$31.2M | -$27.8M | -$201M | -$3.1M | -$3.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$35.0M | -$30.8M | -$202M | -$3.2M | -$3.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$210M | -$21.4M | -$38.3M | -$61.6M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$211M | -$21.3M | -$36.5M | -$61.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-28 · Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing
2026-09-03 · Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 · Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-05 · Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis
2026-08-03 · Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-29 · Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating
2026-07-27 · Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target
2026-07-17 · Damora Therapeutics Completes Redomestication to Cayman Islands
2026-07-17 · Damora Announces Redomestication from Delaware to Cayman Islands
Price (daily)
Full chart · RSI · MACD · patterns